1.
Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Andreas Viardot, Heinz A. Horst, Svenja Neumann, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Dorothea Wessiepe, Max S. Topp, Ralf Bargou. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. haematol [Internet]. 2017Apr.1 [cited 2021Mar.8];102(4):e132-e135. Available from: https://haematologica.org/article/view/8049